Back to Search Start Over

Low-frequency repetitive transcranial magnetic stimulation over the right orbitofrontal cortex for patients with first-episode schizophrenia: A randomized, double-blind, sham-controlled trial.

Authors :
Hu, Qiang
Jiao, Xiong
Zhou, Jie
Tang, Yingying
Zhang, Tianhong
Song, Chuanfu
Wang, Junjie
Xiao, Qiang
Ye, Junying
Sun, Junfeng
Wang, Xijin
Li, Chunbo
Wang, Jijun
Source :
Psychiatry Research. Dec2023, Vol. 330, pN.PAG-N.PAG. 1p.
Publication Year :
2023

Abstract

• This is the first study to explore the therapeutic effect of 1 Hz rTMS over right orbitofrontal cortex (OFC) in patients with first-episode schizophrenia. • 1Hz rTMS applied to the right orbitofrontal cortex can improve psychotic symptoms and cognitive deficits in patients with drug-naïve, first-episode schizophrenia. Repetitive transcranial magnetic stimulation (rTMS) has been used in the treatment of patients with schizophrenia. The conventional targets of rTMS treatment are the dorsolateral prefrontal cortex (DLPFC) and temporoparietal cortex (TPC). However, the efficacy of these two treatment strategies was quite heterogeneous. Structural and functional abnormalities of the orbitofrontal cortex (OFC) in schizophrenia are closely related to negative symptoms. We sought to determine whether 1 Hz rTMS over the right OFC is effective in treating patients with first-episode schizophrenia. In this study, eighty-nine patients with drug-naïve, first-episode schizophrenia were randomly divided into the rTMS (n = 47) or sham stimulation (n = 42) groups, with both groups receiving twenty sessions of 1 Hz rTMS treatment. The PANSS was assessed at baseline, day 10, and day 20, and MATRICS Consensus Cognitive Battery (MCCB) was implemented to assess the cognitive impairment at baseline and day 20. Results showed that patients in the active rTMS group had more improvement in clinical symptoms and cognitive deficits than patients in sham group at day 20. In conclusion, 1 Hz rTMS over OFC can improve psychotic symptoms and cognitive functions in schizophrenic patients. Our study provides a new alternative for the treatment of negative symptoms and cognitive deficits in schizophrenia. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
01651781
Volume :
330
Database :
Academic Search Index
Journal :
Psychiatry Research
Publication Type :
Academic Journal
Accession number :
173969091
Full Text :
https://doi.org/10.1016/j.psychres.2023.115600